Shares of Medidata Solutions, Inc. (NASDAQ:MDSO) have earned an average rating of “Buy” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $84.64.
Several research firms recently commented on MDSO. Piper Jaffray Companies upped their price target on shares of Medidata Solutions to $87.00 and gave the company an “overweight” rating in a research note on Friday, July 7th. Jefferies Group LLC restated a “hold” rating and issued a $78.00 price target on shares of Medidata Solutions in a research note on Tuesday, August 22nd. Citigroup Inc. restated a “buy” rating and issued a $95.00 price target (up from $94.00) on shares of Medidata Solutions in a research note on Monday, July 24th. Morgan Stanley set a $74.00 price target on shares of Medidata Solutions and gave the company a “buy” rating in a research note on Wednesday, June 14th. Finally, BidaskClub upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st.
Medidata Solutions (NASDAQ:MDSO) traded down 0.49% during trading on Wednesday, hitting $80.62. 281,040 shares of the stock were exchanged. Medidata Solutions has a 52 week low of $46.10 and a 52 week high of $85.92. The stock has a market capitalization of $4.56 billion, a price-to-earnings ratio of 130.24 and a beta of 1.77. The firm has a 50-day moving average of $75.52 and a 200-day moving average of $72.11.
Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The firm had revenue of $137.41 million for the quarter, compared to the consensus estimate of $134.28 million. During the same period in the previous year, the company earned $0.24 earnings per share. The company’s quarterly revenue was up 19.9% on a year-over-year basis. Equities research analysts anticipate that Medidata Solutions will post $1.29 earnings per share for the current fiscal year.
In related news, COO Michael L. Capone sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total transaction of $372,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.80% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of MDSO. World Asset Management Inc bought a new stake in Medidata Solutions during the first quarter worth about $201,000. UBS Asset Management Americas Inc. lifted its position in Medidata Solutions by 16.7% during the first quarter. UBS Asset Management Americas Inc. now owns 29,724 shares of the company’s stock worth $1,715,000 after purchasing an additional 4,251 shares during the period. Karp Capital Management Corp bought a new stake in Medidata Solutions during the first quarter worth about $641,000. Sei Investments Co. lifted its position in Medidata Solutions by 18.9% during the first quarter. Sei Investments Co. now owns 35,919 shares of the company’s stock worth $2,073,000 after purchasing an additional 5,709 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its position in Medidata Solutions by 1.8% during the first quarter. Parametric Portfolio Associates LLC now owns 91,576 shares of the company’s stock worth $5,283,000 after purchasing an additional 1,618 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with our FREE daily email newsletter.